FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313405430> ?p ?o ?g. }

• W4313405430 endingPage "923" @default.
• W4313405430 startingPage "915" @default.
• W4313405430 abstract "Abstract Despite the introduction of multiple new drugs and combination therapies, conventional dexamethasone remains a cornerstone in the treatment of multiple myeloma (MM). Its application is, however, limited by frequent adverse effects of which the increased infection rate may have the strongest clinical impact. The efficacy-safety ratio of dexamethasone in MM may be increased by encapsulation in long-circulating PEG-liposomes, thereby both enhancing drug delivery to MM lesions and reducing systemic corticosteroid exposure. We evaluated the preliminary safety and feasibility of a single intravenous (i.v.) infusion of pegylated liposomal dexamethasone phosphate (Dex-PL) in heavily pretreated relapsing or progressive symptomatic MM patients within a phase I open-label non-comparative interventional trial at two dose levels. In the 7 patients that were enrolled (prior to having to close the study prematurely due to slow recruitment), Dex-PL was found to be well tolerated and, as compared to conventional dexamethasone, no new or unexpected adverse events were detected. Pharmacokinetic analysis showed high and persisting concentrations of dexamethasone in the circulation for over a week after i.v. administration, likely caused by the long-circulation half-life of the liposomes that retain dexamethasone as the inactive phosphate prodrug form, something which could significantly limit systemic exposure to the active parent drug. Thus, despite the limitations of this small first-in-man trial, Dex-PL seems safe and well tolerated without severe side effects. Follow-up studies are needed to confirm this in a larger patient cohort and to evaluate if i.v. Dex-PL can provide a safer and more efficacious dexamethasone treatment option for MM. Graphical Abstract" @default.
• W4313405430 created "2023-01-06" @default.
• W4313405430 creator A5002753518 @default.
• W4313405430 creator A5003895825 @default.
• W4313405430 creator A5018099107 @default.
• W4313405430 creator A5018668911 @default.
• W4313405430 creator A5022062256 @default.
• W4313405430 creator A5028314781 @default.
• W4313405430 creator A5046358594 @default.
• W4313405430 creator A5079522186 @default.
• W4313405430 creator A5090048856 @default.
• W4313405430 creator A5090648381 @default.
• W4313405430 date "2023-01-02" @default.
• W4313405430 modified "2023-10-14" @default.
• W4313405430 title "A phase I first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone in patients with progressive multiple myeloma" @default.
• W4313405430 cites W1535876276 @default.
• W4313405430 cites W1579809147 @default.
• W4313405430 cites W1585705786 @default.
• W4313405430 cites W1591670127 @default.
• W4313405430 cites W1970649283 @default.
• W4313405430 cites W1975783065 @default.
• W4313405430 cites W1978643311 @default.
• W4313405430 cites W1989259853 @default.
• W4313405430 cites W1997338521 @default.
• W4313405430 cites W2000763979 @default.
• W4313405430 cites W2001141315 @default.
• W4313405430 cites W2004550095 @default.
• W4313405430 cites W2025924761 @default.
• W4313405430 cites W2042342219 @default.
• W4313405430 cites W2044436186 @default.
• W4313405430 cites W2054383376 @default.
• W4313405430 cites W2063838991 @default.
• W4313405430 cites W2074544404 @default.
• W4313405430 cites W2077129199 @default.
• W4313405430 cites W2079067522 @default.
• W4313405430 cites W2086061986 @default.
• W4313405430 cites W2120929463 @default.
• W4313405430 cites W2124586897 @default.
• W4313405430 cites W2132910786 @default.
• W4313405430 cites W2142723984 @default.
• W4313405430 cites W2151888386 @default.
• W4313405430 cites W2152124092 @default.
• W4313405430 cites W2161580101 @default.
• W4313405430 cites W2169222334 @default.
• W4313405430 cites W2169336006 @default.
• W4313405430 cites W2169794253 @default.
• W4313405430 cites W2407107826 @default.
• W4313405430 cites W2416159780 @default.
• W4313405430 cites W2750556669 @default.
• W4313405430 cites W2781388087 @default.
• W4313405430 cites W2948728876 @default.
• W4313405430 cites W2949123718 @default.
• W4313405430 cites W3034087788 @default.
• W4313405430 cites W3046016469 @default.
• W4313405430 cites W3083633589 @default.
• W4313405430 cites W3121123153 @default.
• W4313405430 cites W3194197143 @default.
• W4313405430 cites W3202147316 @default.
• W4313405430 cites W4200383069 @default.
• W4313405430 cites W4252175385 @default.
• W4313405430 doi "https://doi.org/10.1007/s13346-022-01268-6" @default.
• W4313405430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36592287" @default.
• W4313405430 hasPublicationYear "2023" @default.
• W4313405430 type Work @default.
• W4313405430 citedByCount "0" @default.
• W4313405430 crossrefType "journal-article" @default.
• W4313405430 hasAuthorship W4313405430A5002753518 @default.
• W4313405430 hasAuthorship W4313405430A5003895825 @default.
• W4313405430 hasAuthorship W4313405430A5018099107 @default.
• W4313405430 hasAuthorship W4313405430A5018668911 @default.
• W4313405430 hasAuthorship W4313405430A5022062256 @default.
• W4313405430 hasAuthorship W4313405430A5028314781 @default.
• W4313405430 hasAuthorship W4313405430A5046358594 @default.
• W4313405430 hasAuthorship W4313405430A5079522186 @default.
• W4313405430 hasAuthorship W4313405430A5090048856 @default.
• W4313405430 hasAuthorship W4313405430A5090648381 @default.
• W4313405430 hasBestOaLocation W43134054301 @default.
• W4313405430 hasConcept C108215921 @default.
• W4313405430 hasConcept C112705442 @default.
• W4313405430 hasConcept C126322002 @default.
• W4313405430 hasConcept C197934379 @default.
• W4313405430 hasConcept C2776364478 @default.
• W4313405430 hasConcept C2776804153 @default.
• W4313405430 hasConcept C2780035454 @default.
• W4313405430 hasConcept C2780401358 @default.
• W4313405430 hasConcept C71924100 @default.
• W4313405430 hasConcept C90924648 @default.
• W4313405430 hasConcept C98274493 @default.
• W4313405430 hasConceptScore W4313405430C108215921 @default.
• W4313405430 hasConceptScore W4313405430C112705442 @default.
• W4313405430 hasConceptScore W4313405430C126322002 @default.
• W4313405430 hasConceptScore W4313405430C197934379 @default.
• W4313405430 hasConceptScore W4313405430C2776364478 @default.
• W4313405430 hasConceptScore W4313405430C2776804153 @default.
• W4313405430 hasConceptScore W4313405430C2780035454 @default.
• W4313405430 hasConceptScore W4313405430C2780401358 @default.
• W4313405430 hasConceptScore W4313405430C71924100 @default.
• W4313405430 hasConceptScore W4313405430C90924648 @default.

• next